Massive study of 22 million seniors tests pneumonia Vaccine's Real-World power
NCT ID NCT06782282
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how effective the Prevnar 20 (PCV20) vaccine is at preventing serious lung infections in people aged 65 and older. Researchers will analyze medical records from over 22 million Medicare beneficiaries, comparing those who got the vaccine to those who did not. The goal is to see if the vaccine reduces cases of pneumonia and other lower respiratory infections in real-world conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Prevnar 20 (20-valent pneumococcal conjugate vaccine, PCV20)
- What this could lead to
- If successful, this could confirm that the PCV20 vaccine effectively prevents serious lung infections in older adults, supporting its widespread use.
- What could go wrong
- This is an observational study using existing data, not a controlled trial, so results may be influenced by unmeasured factors. It does not test new treatments or vaccines.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMMUNITY-ACQUIRED PNEUMONIA (CAP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer United States
New York, New York, 10017, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New antibiotic lefamulin takes on Drug-Resistant pneumonia
- Could your Child's cough help diagnose asthma or pneumonia?
- Herbal formula NRICM102 tested as pneumonia Add-On treatment
- Pneumonia drug trial aims to protect arteries from hidden damage
- Could less be more? new trial tests lower antibiotic dose for pneumonia
- Promising pneumonia therapy trial pulled before it began